JCOG1008长期随访:术后高危头颈鳞癌每周顺铂方案非劣于三周方案
JCOG1008为II/III期随机试验,纳入261例术后高危局部晚期头颈鳞癌患者,比较每周顺铂(40 mg/m2,共7次)与三周顺铂(100 mg/m2,共3次)化放疗。中位随访5.6年时,5年总生存率分别为71.2%与58.7%(HR 0.76,95%CI 0.52~1.12),确证每周方案非劣效;两组晚期不良事件差异均未超过10%。
要点
- 中位随访5.6年,每周顺铂组5年OS为71.2%,三周组为58.7%,HR 0.76(95%CI 0.52~1.12),非劣效成立。
- 每周组5年无复发生存与局部无复发生存数值上均优于三周组。
- 两臂晚期不良事件差异均未超过10%,每周顺铂联合放疗可作为合理替代方案。
核心结论
- 5年随访证实,术后高危LA-SCCHN患者中每周顺铂化放疗在OS上非劣于三周顺铂化放疗。
- 结果进一步支持每周顺铂联合放疗作为该人群的合理替代方案。
研究设计与样本
- JCOG1008为随机II/III期试验,入组术后高危局部晚期头颈鳞状细胞癌(LA-SCCHN)患者。
- 共纳入261例患者,随机接受三周顺铂或每周顺铂化放疗。
主要发现
- 中位随访5.6年,5年OS在三周组为58.7%、每周组为71.2%(HR 0.76,95%CI 0.52~1.12)。
- 5年无复发生存(RFS)与5年局部RFS在每周组数值上更优。
- 两臂间无晚期不良事件差异超过10%。
关键数值与推荐
- 每周顺铂剂量为40 mg/m2,每周1次共7次;三周顺铂为100 mg/m2,每3周1次共3次。
- 非劣效性以OS的HR及95%CI评估,最终分析HR 0.76(95%CI 0.52~1.12)。
临床怎么用
- 术后高危LA-SCCHN可考虑每周顺铂联合放疗作为三周顺铂方案的替代选择。
- 选择方案时结合长期生存获益与晚期毒性谱进行个体化决策。
局限性
- 长期随访报告为JCOG1008的更新分析,样本量为261例。
- 晚期不良事件仅以两臂差异是否超过10%描述,未报告具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm. No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.
引用
- Tahara M, Kiyota N, Kodaira T, et al. Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. J Clin Oncol. 2026. PMID: 42361282. doi:10.1200/JCO-25-01708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。